DBV Technologies S.A. (DBVT) Dividend History

Company News

• DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

  DBV Technologies, a biopharmaceutical company, announced the filing of its 2024 Annual Report and Universal Registration Document, which include audited financial statements and other regulatory filings.

  GlobeNewswire Inc.
• DBV Technologies Announces Plan to Implement ADS Ratio Change

  DBV Technologies, a biopharmaceutical company, announced plans to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares from 1:1 to 1:5. This change is intended to enable the company to regain compliance with the Nasdaq minimum bid price requirement.

  GlobeNewswire Inc.
• DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

  DBV Technologies announced positive regulatory updates for its Viaskin Peanut patch in the US and Europe, including an accelerated approval pathway in the US for toddlers and a registration path in Europe for children aged 1-7 years.

  GlobeNewswire Inc.
• DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en Europe

  DBV Technologies announced positive regulatory progress for its Viaskin Peanut patch, including accelerated approval in the US for children aged 1-3 and confirmation of the registration procedure in Europe for children aged 1-7.

  GlobeNewswire Inc.
• DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

  DBV Technologies, a biopharmaceutical company, announced its participation in the upcoming ACAAI 2024 Congress, including a product theater discussion on optimal peanut allergy treatment and sponsorship of the FIT Bowl competition.

  GlobeNewswire Inc.